Strides Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹1,430 crore and net profit of ₹134 crore for the September 2026 quarter.
Strides Pharma (NSE: STAR) closed at ₹967.30 on 20 Nov 2026, up 4.8% over the past year. Its market capitalisation is ₹8,917 crore and it trades at 15.5 times earnings.
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company's pharmaceutical products are sold in over 100 countries. The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.